Blood-Based Biomarkers for Mild Traumatic Brain Injury: How and Why We Implemented Them at Our

Monday, September 8
Presented by: bioMerieux, Inc.

• Speaker: Jeniel Parmar, MD, PhD, Emergency Medicine Attending Physician, Associate Medical Director, Boca Raton Fire and Rescue, Associate Medical Director, Highland Beach Fire and Rescue
• Time: 2:30pm – 3:15pm
• Location: Exhibit Hall, Expert Theater 2

Each year, an estimated 2.8–4.8 million Americans are diagnosed with traumatic brain injury^1,2. The vast majority of these presentations will be characterized as mild^3,4. Join us to learn the impact of blood-based diagnostics on the workup of these patients and the health systems that adopt them. Hear from Dr. Jeniel Parmar on his experience implementing the VIDAS® TBI (GFAP, UCH-L1) assay at Boca Raton Regional Hospital. During this interactive session, we will explore the following:

• The potential of these proteins to optimize patient throughput and efficiency.
• Assay impact on resource stewardship, clinical decision making, and reducing unnecessary exposure to ionizing radiation.
• How blood-based biomarkers may contribute to reducing healthcare-associated cost and burden.

References:

1. CDC. Surveillance Report of Traumatic Brain injury-related Emergency Department Visits, Hospitalizations, and Deaths, 2014
2. J Head Trauma Rehabil, 2016. 31(6): p. 379-387
3. J Rehabil Med. 2004;43 (Suppl):28–60
4. J Neurosurg. 2019. 130:1080–1097